Oleoylethanolamide (OEA) is an endogenous fatty acid amide (COOH N) that belongs to the ethanolamide family.
It is a biologically active (bioactive) mono-unsaturated lipid mediator.
OEA is derived from oleic acid, an 18-carbon monounsaturated fatty acid (18:1, n-9), and is synthesised in the gastrointestinal tract (intestinal epithelial cells (enterocytes), fat tissues, neurons, and astrocytes.
Trpti™ is a novel ingredient that contains a combination of Oleoylethanolamide (OEA) with LipiSperse® dispersion technology.
LipiSperse® is a cold-water dispersion technology designed to promote the solubility and bioavailability of lipophilic compounds such as OEA and contains no bioactive properties itself.
The technology makes use of surfactants, polar lipids, and solvents that embed into OEA’s crystal structure whilst:
Enhanced glycaemic control
Promotes glycogen synthesis (glycogenesis) and suppresses liver glucose production (gluconeogenesis) by activating liver kinase B1 (LKB1) and 5’ AMP-activated protein kinase (AMPK) signaling pathways in the liver
Lower blood glucose levels
Reduced postprandial glucose levels
Lower insulin levels
Lower HOMA-IR (Homeostatic Model Assessment of Insulin Resistance)
Promotes fatty acid oxidation
Improved triglyceride metabolism
Increased HDL-C
Reduced ALT and AST liver enzyme concentrations
Reduced:
Interleukin-6 (IL-6)
Tumour necrosis factor-alpha (TNF-α)
C-Reactive Protein (CRP)
Expression and signalling of nuclear factor-kappa B (NF-κB)
Activates:
Peroxisome proliferator-activated receptor alpha (PPAR-α)
Increased total antioxidant capacity (TAC)
Increased superoxide dismutase (SOD)
Reduced malondialdehyde (MDA)
Reduced oxidised LDL (ox-LDL)
Suppresses general ROS
Delayed meal initiation
Appetite regulation and suppressed appetite
Enhanced satiety
Energy and carbohydrate intakes decreased
Decreased cravings for sweet foods
Decreased gastric emptying
Reduced body weight.
Reduced BMI
Reduced waist circumference
Reduced body fat percentage
Reduced fat mass
Increased feelings of fullness
300 mg of TRPTI™ (providing 250 mg/day of OEA) or Placebo for 12 weeks.
OEA was safe and well-tolerated with no adverse changes in clinical biomarkers.
Results
Increased:
Additionally:
Notes
Adults only. Not recommended for children, pregnant, or breastfeeding individuals.
For information purposes only. Not a substitute for medical advice. If symptoms persist, talk to a health professional. Always read the label. Follow the directions for use.